Connect with us

Category 2

Research roundup: Discover the latest research and developments in fem tech

Published

on

Fem Tech World explores the latest research developments impacting on women’s health.

AI system detects heart defects on foetal ultrasound exams

A new study has evaluated whether an artificial intelligence (AI) system can improve the detection of congenital heart defects on foetal ultrasound exams among both general OBGYNs and maternal foetal medicine specialists.

The team found that assistance by the AI system significantly improved detection of studies suspicious for congenital heart defects. AI may play a pivotal role in improving prenatal detection of CHD.

Inhibitor drugs to treat aggressive breast cancer identified

Two inhibitor drugs with the potential to interrupt disease progression have been identified in a new study.

By examining the biology of metaplastic breast cancer and comparing it to non-metaplastic triple negative breast cancer, a team of researchers have discovered metaplastic breast cancers typically exhibit two unique signalling pathways in their cell interaction.

The team were able to disrupt these pathways using a class of inhibitors typically used to treat advanced cancers – phosphoinositide 3 kinase inhibitor (P13K) – in combination with a nitric oxide inhibitor (NOS) typically used to treat septic shock, cardiovascular disease and other conditions.

When introduced to the cell, these drugs disrupted these pathways, making the treatment more effective.

The team say the findings offer a promising therapeutic option for one of the most aggressive and difficult-to-treat subtypes of breast cancer.

Could the contraceptive pill reduce risk of ovarian cancer?

The oral contraceptive pill reduced the risk of ovarian cancer by 26 per cent among women who had ever used the Pill, and by 43 per cent for women who had used the Pill after the age of 45, a new study has found.

Biomarkers associated with ovarian cancer risk were also identified in the study, including several characteristics of red blood cells and certain liver enzymes in the blood, with lower body weight and shorter stature associating with a lower risk of ovarian cancer.

Researchers also found that women who had given birth to two or more children had a 39 per cent reduced risk of developing ovarian cancer compared to those who had not had children.

Maternal biomarker test significantly reduces neonatal morbidities

A biomarker test to identify pregnant people at higher risk of preterm birth significantly improved neonatal outcomes, including reducing infant morbidity as well as reducing admissions to the neonatal intensive care unit (NICU) and the amount of time spent in the NICU.

In a clinical trial, the biomarker test, which analysed a participant’s blood, was administered in the middle of the second trimester of pregnancy to identify individuals at higher risk of delivering an infant preterm.

The test classified 23.5 percent of participants as higher risk within the preterm birth prevention arm. In addition to the traditional standard of care, individuals identified as high risk were given a low-risk and low-cost regimen of daily vaginal progesterone and low-dose aspirin and also assigned weekly standardised phone calls with a nurse.

The researchers say that the findings suggest a transformative strategy for reducing neonatal complications.

No evidence that maternal sickness during pregnancy causes autism

Of the few conditions truly associated with autism, a new study reveals that all of them are actually complications with the foetus — leading the authors to believe that those symptoms were early signs of autism in the child and not the cause of it.

The study included an analysis of the medical histories of more than 1.1 million pregnancies (among 600,000 mothers) from a national registry in Denmark.

The researchers corrected for factors that could confound, or offer an alternative explanation for, the link between the diagnosis a woman received and a child’s autism diagnosis.

These factors include sociodemographic status and the mother’s age during pregnancy, since children of older mothers are more likely to be diagnosed with autism, and their mothers are also more likely to receive certain diagnoses, such as hypertension, than their younger counterparts.

After accounting for these confounding factors, as well as for concurrent diagnoses, 30 were still statistically associated with autism in the child.

To determine if these happened to occur alongside rather than cause autism, the researchers then included the siblings of autistic children in the analysis. If a mother was diagnosed with the same condition during pregnancies of children with and without autism, then it would suggest that factors other than her diagnosis were influencing the link with autism.

The researchers say their interpretation is that these foetal diagnoses likely do not cause autism, but are instead early signs of it.

Opinion

Hinge charts pelvic pain breakthrough in latest trial

Published

on

A women’s health intervention that harnesses software, AI and wearables to address pelvic pain, as well as depression, has shown promising results.

Hinge Health’s digital ‘Women’s Pelvic Health Programme’ has reported a 44 per cent reduction in pelvic pain after four weeks of use – and 53 per cent after 12 weeks.

The probability of the intervention group screening for moderate to severe depression was significantly lower by 11 per cent compared to the control group.

Bijal Toprani, pelvic health physical therapist at Hinge Health and co-author of the study, said: “Although women’s pelvic pain is incredibly common, it remains undertreated and as a result, many women are going about their lives suffering in silence.

“This study builds on validated research supporting the efficacy of Hinge Health’s Women’s Pelvic Health program to make a tangible impact for women and improve their quality of life.”

The findings were published in the medical journal, BMC Women’s Health.

One in three women will suffer a pelvic floor disorder in their lifetime.

These disorders occur when pelvic floor muscles become weak or tight. Women with chronic pelvic pain experience a wide range of physical and psychological challenges related to their condition, from urinary urgency and constipation to lower back and hip pain.

Some common causes are muscle strain during pregnancy, trauma or injury to the pelvic floor from surgery or childbirth, hormonal changes with menopause, and stress or anxiety triggering tension in the pelvic floor.

This pain can take a toll on a woman’s overall wellbeing, impacting both their personal and professional lives.

In addition to a lack of awareness around pelvic health issues, inadequate access to pelvic floor specialists makes it difficult for women to find care, making digital solutions essential.

Hinge Health’s 2025 State of MSK Care Report found that while it can take an average of 93 days to see a pelvic floor physical therapist (PT) in person.

“Pelvic floor problems are treatable, however, a major problem is simply access to specialists,” said Dr. Jeff Krauss, CMO at Hinge Health.

“This study is an achievement demonstrating the strengths of our digital Women’s Pelvic Health Program and sends an encouraging message to women that there are clinically-validated, easily-accessible programmes available to help them.”

This observational study examined pain, depression, and anxiety outcomes at four and 12 weeks among participants of a digital women’s pelvic health program compared to a non-participant group. A total of 797 participants were included in the sample.

The company is headquartered in San Francisco.

Continue Reading

Pregnancy

New Visa programme could boost femtech founders amid investment gap

Published

on

Femtech startups may be able to access a new investment scheme from Visa, which aims to close the funding gap experienced by female founders.

Visa Foundaton has launched the CatalyseHer Programme in the UK and is aiming to provide 500 women entrepreneurs with training and fundraising support to grow their businesses and make them more attractive to investors.

The programme includes training, networking and micro-grants and is aimed at early stage, women-owned businesses.

It is seeking to 500 UK-based female founders to address the gender financing gap facing women entrepreneurs in the UK.

Women entrepreneurs still face barriers when it comes to access to the investments and resources that support innovation.

Women-founded businesses in the UK receive only a two per cent share of total venture capital investments according to the British Business Bank.

Najada Kumbuli, head of investments and partnerships, Visa Foundation said: “Women entrepreneurs play a crucial role in all economies by driving innovation and impact at scale.

“This programme aims to address the main challenges faced by women entrepreneurs and create a ripple effect across many communities in the UK.”

Mandy Lamb, MD in the UK and Ireland at Visa, said: “Women entrepreneurs are critical in developing a more sustainable, equitable future. By addressing barriers and providing access to resources such as funding, mentorship and networking, Visa Foundation can help unlock the potential of women-led businesses to drive further innovation in the UK.”

CatalyseHer is supported by the social enterprise IMCO. See more on the programme here.

Visa also runs the ‘She’s Next’ programme, a global initiative to spotlight women in their efforts to fund, run, and grow their businesses.

Launched in January 2019, it has invested £2.5+m in grants and coaching for female business owners across Europe.

Continue Reading

Category 2

GE aims to alleviate high risk pregnancy issues with latest release

Published

on

Global health products giant GE Healthcare has launched new AI-powered ultrasound tech which it says could improve the diagnosis and monitoring of high-risk pregnancies.

The multinational has received FDA clearance in the US for the updated version of its Voluson Expert series of ultrasound systems.

The tech features AI-driven functionality and tools which it says will support faster assessments and early detection, diagnosis and intervention.

Its ‘SonoLyst’ suite of AI tools is designed to simplify exams via image recognition and automated annotations and measurements.

The new system also provides a graphical representation of the trajectories of the blood cells in real-time to visualise complex blood flow, helping users differentiate normal from abnormal hemodynamics.

In the US alone, approximately 30,000 to 50,000 women experience complex, high-risk pregnancy each year.

When these complications are left undetected or untreated, it may harm the mother or the baby. GE says that the growing prevalence of these complications underscores the need for innovative solutions that enable early detection and intervention.

Gerald Seifriedsberger, general manager, women’s health, advanced visualization solutions ar GE HealthCare, says: “We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women’s health needs of today, and the future.

“By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach healthcare. Together, we can create a healthier future for all women.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.